论文部分内容阅读
目的探讨干扰素α-2b、苦参素与胸腺肽联合治疗慢性乙型肝炎的临床疗效。方法选择我院2007年3月～2009年3月慢性乙型肝炎患者82例,将以上患者随机分为两组,观察组和对照组。两组患者均给予常规性保肝治疗。在以上治疗基础上观察组患者给予干扰素α-2b,隔日肌肉注射一次,每次500万IU;给予苦参素胶囊200mg口服,每天3次;给予胸腺肽α11.6mg,皮下注射,每周2次,以上共应用13周;接下来13周内只应用干扰素和胸腺肽α1,具体用药方法同上;接下来26周内单独应用干扰素,具体用法同上。对照组患者单独应用干扰素α-2b,隔日肌肉注射一次,每次500万IU,连续应用52周。结果观察组ALT复常率、HBeAg/抗-HBe血清转换率、HBV-DNA阴转率和HA复常率分别与对照组比较,差异有统计学意义(P<0.05)。结论干扰素α-2b、苦参素与胸腺肽联合治疗慢性乙型肝炎临床效果显著,值得借鉴。
Objective To investigate the clinical efficacy of interferon α-2b, oxymatrine and thymosin in the treatment of chronic hepatitis B patients. Methods 82 patients with chronic hepatitis B from March 2007 to March 2009 in our hospital were randomly divided into two groups: observation group and control group. Two groups of patients were given conventional liver protection. On the basis of the above treatment, patients in the observation group were given interferon alpha-2b and intramuscular injection every other day for 5 million IU; oxymatrine capsule 200 mg orally three times a day; thymosin alpha 11.6 mg given subcutaneously 2 Times, the above application of a total of 13 weeks; the next 13 weeks, only the application of interferon and thymosin α1, the specific use of drugs as above; the next 26 weeks of interferon alone, the specific usage ibid. Patients in the control group received interferon alpha-2b alone and were injected intramuscularly every other day for 5 million IU for 52 weeks. Results The ALT normalization rate, HBeAg / anti-HBe conversion rate, HBV-DNA negative conversion rate and HA recovery rate in the observation group were significantly different from those in the control group (P <0.05). Conclusion Interferon α-2b, oxymatrine and thymosin combined treatment of chronic hepatitis B clinical effect is significant, it is worth learning from.